Cargando…

Nonmuscle invasive bladder cancer: a primer on immunotherapy

Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruf, Mahir, Brancato, Sam J., Agarwal, Piyush K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944546/
https://www.ncbi.nlm.nih.gov/pubmed/27458527
http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0020
_version_ 1782442783641960448
author Maruf, Mahir
Brancato, Sam J.
Agarwal, Piyush K.
author_facet Maruf, Mahir
Brancato, Sam J.
Agarwal, Piyush K.
author_sort Maruf, Mahir
collection PubMed
description Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeutics in the treatment of nonmuscle invasive bladder cancer.
format Online
Article
Text
id pubmed-4944546
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-49445462016-07-25 Nonmuscle invasive bladder cancer: a primer on immunotherapy Maruf, Mahir Brancato, Sam J. Agarwal, Piyush K. Cancer Biol Med Review Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeutics in the treatment of nonmuscle invasive bladder cancer. Chinese Anti-Cancer Association 2016-06 /pmc/articles/PMC4944546/ /pubmed/27458527 http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0020 Text en Copyright 2016 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Review
Maruf, Mahir
Brancato, Sam J.
Agarwal, Piyush K.
Nonmuscle invasive bladder cancer: a primer on immunotherapy
title Nonmuscle invasive bladder cancer: a primer on immunotherapy
title_full Nonmuscle invasive bladder cancer: a primer on immunotherapy
title_fullStr Nonmuscle invasive bladder cancer: a primer on immunotherapy
title_full_unstemmed Nonmuscle invasive bladder cancer: a primer on immunotherapy
title_short Nonmuscle invasive bladder cancer: a primer on immunotherapy
title_sort nonmuscle invasive bladder cancer: a primer on immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944546/
https://www.ncbi.nlm.nih.gov/pubmed/27458527
http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0020
work_keys_str_mv AT marufmahir nonmuscleinvasivebladdercanceraprimeronimmunotherapy
AT brancatosamj nonmuscleinvasivebladdercanceraprimeronimmunotherapy
AT agarwalpiyushk nonmuscleinvasivebladdercanceraprimeronimmunotherapy